CAR T for autoimmune disease benefits from oncology’s lessons—and will deliver its own

Summary

CAR T cell therapy, originally developed for blood cancers, is expanding into autoimmune disease treatment applications and showing clinical promise. The modality is expected to deliver broader therapeutic benefits by applying oncology-derived lessons to autoimmune indications.